Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Carmen Guerra

Carmen Guerra

Staff Scientist at CNIO, Co-Senior Author

Appears in 1 story

Notable Quotes

"KRAS inhibitors are yielding better results than chemotherapy, but ultimately resistance appears. That's why we are investigating the molecular mechanism of these resistances."

Stories

The race to drug KRAS in pancreatic cancer

New Capabilities

Named in PNAS retraction for undisclosed financial stake in Vega Oncotargets; paper resubmitted through standard peer review

On May 31, Revolution Medicines presented the full Phase 3 RASolute 302 dataset at the ASCO plenary in Chicago, simultaneously published in the New England Journal of Medicine. Daraxonrasib cut the risk of death by 60%. The drug produced a 33.2% objective response rate versus 11.8% on chemotherapy and nearly halved the rate at which patients' pain worsened.

Updated Jun 8